Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Moyes Eye Center PC

Neither a doctor nor a teaching hospital

Research payments

$1,051,206

124 payments

Through program year 2025, Moyes Eye Center PC is reported as receiving $1,051,206 in research payments, across 124 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $139,179 19
2024 Research $98,288 15
2023 Research $157,086 15
2022 Research $221,417 19
2021 Research $71,106 16
2020 Research $184,527 19
2019 Research $179,603 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $433,764 54 payments
  2. Sight Sciences, Inc. $293,125 6 payments
  3. AbbVie, Inc. $178,819 37 payments
  4. Oyster Point Pharma, Inc. $137,861 22 payments
  5. Shire North American Group Inc $7,027 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $609 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) $293,125 6 payments
  2. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $147,813 11 payments
  3. A Multicenter, Single-masked, Randomized Study to Compare the Safety and Efficacy of Two Novel Artificial Tear Formulations with Systane Unit Dose for 3 Months in Subjects with Dry Eye Disease $144,411 8 payments
  4. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $122,883 32 payments
  5. A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $98,805 13 payments
  6. A Multicenter, Single-masked, Randomized Study to Compare the Safety and Efficacy of Two Novel Artificial Tear Formulations with Systane Unit Dose for 3 Months in Subjects with Dry Eye Disease $50,899 8 payments
  7. A Phase 2, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $33,607 7 payments
  8. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $29,114 12 payments
  9. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $25,990 9 payments
  10. 1698-301-007 Ph3b Study (M21-488) $24,829 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record